Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial--ANZGOG 0903.

Linda Mileshkin,Richard Edmondson,Rachel O’Connell,Katrin Marie Sjoquist,David Cannan,Rema Jyothirmayi,Philip Beale,Tony Bonaventura,Jeffrey C. Goh,Marcia Hall,Andrew R Clamp,John Green,Rosemary Lord,James Scurry,Michael Friedlander

Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial--ANZGOG 0903.

2016

Linda Mileshkin
Richard Edmondson
Rachel O’Connell
Katrin Marie Sjoquist
David Cannan
Rema Jyothirmayi
Philip Beale
Tony Bonaventura
Jeffrey C. Goh
Marcia Hall
Andrew R Clamp
John Green
Rosemary Lord
James Scurry
Michael Friedlander

5520Background: Many endometrial cancers express hormone receptors and may respond to hormonal therapy, but the impact on quality of life (QOL) is unclear. The aim of PARAGON is to investigate anas...

Keywords:

Pathology
Endometrial cancer
Phases of clinical research
Estrogen
Anastrozole
Gynecology
Cancer research
Medicine
Oncology
Internal medicine
Hormonal therapy
Quality of life
Hormone receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations